These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

356 related articles for article (PubMed ID: 24252016)

  • 1. Study on the safety and efficacy of tocilizumab, an anti-IL-6 receptor antibody, in patients with rheumatoid arthritis complicated with AA amyloidosis.
    Miyagawa I; Nakayamada S; Saito K; Hanami K; Nawata M; Sawamukai N; Nakano K; Yamaoka K; Tanaka Y
    Mod Rheumatol; 2014 May; 24(3):405-9. PubMed ID: 24252016
    [TBL] [Abstract][Full Text] [Related]  

  • 2. AA amyloidosis treated with tocilizumab: case series and updated literature review.
    Courties A; Grateau G; Philippe P; Flipo RM; Astudillo L; Aubry-Rozier B; Fabreguet I; Fahd W; Fain O; Guggenbuhl P; Hachulla E; Papo T; Richez C; Sibilia J; Morel J; Berenbaum F; Sellam J;
    Amyloid; 2015; 22(2):84-92. PubMed ID: 25585627
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic blockade of interleukin-6 by tocilizumab in the management of AA amyloidosis and chronic inflammatory disorders: a case series and review of the literature.
    Lane T; Gillmore JD; Wechalekar AD; Hawkins PN; Lachmann HJ
    Clin Exp Rheumatol; 2015; 33(6 Suppl 94):S46-53. PubMed ID: 26120866
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The efficacy and safety of reinstitution of tocilizumab in patients with relapsed active rheumatoid arthritis after long-term withdrawal of tocilizumab: retreatment of patients with rheumatoid arthritis with novel anti-IL-6 receptor antibody after a long-term interval following SAMURAI: the RONIN study.
    Sagawa A
    Mod Rheumatol; 2011 Aug; 21(4):352-8. PubMed ID: 21347804
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tocilizumab for treating rheumatoid arthritis: an evaluation of pharmacokinetics/pharmacodynamics and clinical efficacy.
    Song SN; Yoshizaki K
    Expert Opin Drug Metab Toxicol; 2015 Feb; 11(2):307-16. PubMed ID: 25491492
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of the clinical utility of tocilizumab and anti-TNF therapy in AA amyloidosis complicating rheumatic diseases.
    Okuda Y; Ohnishi M; Matoba K; Jouyama K; Yamada A; Sawada N; Mokuda S; Murata Y; Takasugi K
    Mod Rheumatol; 2014 Jan; 24(1):137-43. PubMed ID: 24261770
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety of subcutaneous versus intravenous tocilizumab in combination with traditional disease-modifying antirheumatic drugs in patients with rheumatoid arthritis.
    McLaughlin M; Östör A
    Expert Opin Drug Saf; 2015 Mar; 14(3):429-37. PubMed ID: 25553607
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tocilizumab preserves renal function in rheumatoid arthritis with AA amyloidosis and end-stage kidney disease: Two case reports.
    Fukuda M; Sawa N; Hoshino J; Ohashi K; Motoaki M; Ubara Y
    Clin Nephrol; 2021 Jan; 95(1):54-61. PubMed ID: 33155543
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Tocilizumab in rheumatoid arthritis].
    Rueda Gotor J; Blanco Alonso R
    Reumatol Clin; 2011 Mar; 6S3():S29-32. PubMed ID: 21794769
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum interleukin 6 before and after therapy with tocilizumab is a principal biomarker in patients with rheumatoid arthritis.
    Shimamoto K; Ito T; Ozaki Y; Amuro H; Tanaka A; Nishizawa T; Son Y; Inaba M; Nomura S
    J Rheumatol; 2013 Jul; 40(7):1074-81. PubMed ID: 23637318
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical strategies for amyloid A amyloidosis secondary to rheumatoid arthritis.
    Nakamura T
    Mod Rheumatol; 2008; 18(2):109-18. PubMed ID: 18369528
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Longterm Safety and Efficacy of Subcutaneous Tocilizumab Monotherapy: Results from the 2-year Open-label Extension of the MUSASHI Study.
    Ogata A; Amano K; Dobashi H; Inoo M; Ishii T; Kasama T; Kawai S; Kawakami A; Koike T; Miyahara H; Miyamoto T; Munakata Y; Murasawa A; Nishimoto N; Ogawa N; Ojima T; Sano H; Shi K; Shono E; Suematsu E; Takahashi H; Tanaka Y; Tsukamoto H; Nomura A;
    J Rheumatol; 2015 May; 42(5):799-809. PubMed ID: 25834203
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tocilizumab in the treatment of twelve cases with aa amyloidosis secondary to familial mediterranean fever.
    Ugurlu S; Hacioglu A; Adibnia Y; Hamuryudan V; Ozdogan H
    Orphanet J Rare Dis; 2017 May; 12(1):105. PubMed ID: 28558744
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of interleukin-6 receptor inhibitor, tocilizumab, in preventing joint destruction in patients with rheumatoid arthritis showing inadequate response to TNF inhibitors.
    Tanaka Y; Takeuchi T; Amano K; Saito K; Hanami K; Nawata M; Fukuyo S; Kameda H; Kaneko Y; Kurasawa T; Nagasawa H; Hoshi D; Sato E; Yamanaka H
    Mod Rheumatol; 2014 May; 24(3):399-404. PubMed ID: 24252045
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tocilizumab in the treatment of patients with rheumatoid arthritis in real clinical practice: results of an Italian observational study.
    Caporali R; Idolazzi L; Bombardieri S; Ferraccioli G; Gerli R; Govoni M; Matucci Cerinic M; Pomponio G; Salaffi F; Tirri R; Benaglio F; Bianchino L; Sarzi-Puttini P;
    Clin Exp Rheumatol; 2017; 35(6):919-928. PubMed ID: 28516890
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Abatacept may be effective and safe in patients with amyloid A amyloidosis secondary to rheumatoid arthritis.
    Nakamura T; Kumon Y; Hirata S; Takaoka H
    Clin Exp Rheumatol; 2014; 32(4):501-8. PubMed ID: 24959698
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High levels of natural killer cells are associated with response to tocilizumab in patients with severe rheumatoid arthritis.
    Daïen CI; Gailhac S; Audo R; Mura T; Hahne M; Combe B; Morel J
    Rheumatology (Oxford); 2015 Apr; 54(4):601-8. PubMed ID: 25231180
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic efficacy of tocilizumab in patients with rheumatoid arthritis refractory to anti-tumor-necrosis-factor inhibitors: 1 year follow-up with low-field extremity MRI.
    Suzuki T; Horikoshi M; Sugihara M; Hirota T; Ogishima H; Umeda N; Kondo Y; Tsuboi H; Hayashi T; Chino Y; Matsumoto I; Sumida T
    Mod Rheumatol; 2013 Jul; 23(4):782-7. PubMed ID: 22975733
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of etanercept in patients with AA amyloidosis secondary to rheumatoid arthritis.
    Nakamura T; Higashi S; Tomoda K; Tsukano M; Baba S
    Clin Exp Rheumatol; 2007; 25(4):518-22. PubMed ID: 17888205
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antiarrhythmic potential of anticytokine therapy in rheumatoid arthritis: tocilizumab reduces corrected QT interval by controlling systemic inflammation.
    Lazzerini PE; Acampa M; Capecchi PL; Fineschi I; Selvi E; Moscadelli V; Zimbone S; Gentile D; Galeazzi M; Laghi-Pasini F
    Arthritis Care Res (Hoboken); 2015 Mar; 67(3):332-9. PubMed ID: 25186226
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.